Susan Stewart

Susan B. Stewart currently works at Regulatory Affairs Professionals Society, as Director, Candel Therapeutics, Inc., as Chief Regulatory Officer from 2020, and Rezolute, Inc., as Chief Regulatory Officer from 2022.
Ms. Stewart also formerly worked at MG Biotherapeutics LLC, as Director, VP-Quality & Regulatory Affairs in 2005, Abbott Laboratories, as Vice President-Regulatory Affairs, Diacrin, Inc. (Delaware), as Principal, Genzyme Corp., as Vice President-Regulatory Affairs from 2001 to 2005, Tokai Pharmaceuticals, Inc., as SVP-Regulatory Affairs, Quality & Compliance from 2009 to 2015, Kaleido Biosciences, Inc., as Chief Regulatory Officer from 2020 to 2022, Frequency Therapeutics, Inc., as Chief Regulatory Officer, resTORbio, Inc., as Head-Regulatory Affairs, and TransMolecular, Inc., as Vice President-Regulatory Affairs from 2005 to 2010.
Ms. Stewart received her undergraduate degree from the University of Massachusetts, graduate degree from Concord Law School, and graduate degree from Maurice A. Deane School of Law at Hofstra University.